Characteristics of patients with cancer and sarcoidosis
| Female n (%) | 72 (54.2) |
| Age at time of sarcoid-like granuloma diagnosis years mean/median | 64.5/65 |
| Underlying cancer n (%) | |
| Skin cancer | 30 (22.5) |
| Breast cancer | 27 (20.3) |
| Lymph cancer | 17 (12.7) |
| Prostate cancer | 14 (10.5) |
| Lung cancer | 12 (9) |
| Colon cancer | 9 (6.7) |
| Urinary bladder cancer | 8(6.0) |
| Cervical cancer | 7 (5.3) |
| Head and neck cancer | 6 (4.5) |
| Sarcoma | 5 (3.8) |
| Kidney cancer | 5 (3.8) |
| Pancreatic cancer | 4 (3.0) |
| Conjunctival cancer | 1 (0.7) |
| Cancer treatment before diagnosis of sarcoidosis n (%) | |
| Surgery | 91 (68.4) |
| Chemotherapy | 54 (40.6) |
| Radiation | 38 (28.6) |
| Chemotherapy agents before diagnosis of sarcoidosis n (%) | |
| Doxorubicin | 15 (11.3) |
| Cisplatin | 11 (8.2) |
| Cyclophosphamide | 11 (8.2) |
| Gemcitabine | 9 (6.7) |
| 5-Fluorouracil | 9 (6.7) |
| Carboplatin | 9 (6.7) |
| Rituximab | 9 (6.7) |
| MAB treatment before cancer diagnosis n (%) | |
| Anti-CD20 | 9 (6.7) |
| PD-1 immune checkpoint | 4 (3) |
| Anti-Her2neu | 2 (1.5) |
| Anti-CTLA4 | 2 (1.5) |
| Anti-VEGF | 1 (0.75) |
| Cancer stage at time of sarcoid-like granuloma diagnosis | |
| Stage 1 | 24 (15.8) |
| Stage 2 | 17 (12) |
| Stage 3 | 18 (12.7) |
| Stage 4 | 12 (7.5) |
| Interval between cancer and sarcoid-like granulomas n(%) | |
| <1 year | 24 (18.9) |
| 1–5 years | 54 (42.5) |
| >5 years | 49 (38.5) |
| Most common symptom at time of sarcoidosis diagnosis n (%) | |
| Dyspnoea | 20 (15) |
| Cough | 18 (13.5) |
| Fatigue | 16 (12) |
| Smoking n (%) | |
| Current | 7 (5.2) |
| Past | 48 (36.1) |
| Never smoker | 76 (57.1) |
| Mean number of years of smoking | 28.5 |
| Sarcoidosis stage at the time of diagnosis n (%) | |
| Stage 1 | 51 (38.3) |
| Stage 2 | 73 (54.9) |
| Stage 3 | 5 (3.7) |
| Stage 4 | 2 (1.5) |